Search
Dextropropoxyphene
go.drugbank.com/drugs/DB00647ApprovedIllicitWithdrawnIt is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. … Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeRifabutin
go.drugbank.com/drugs/DB00615ApprovedInvestigationalA broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.
Categories: Drugs for Treatment of Tuberculosis, Heterocyclic Compounds with 4 or More RingsProducts: Mycobutin 150 mg - Kapseln, RIFBUTIN® 150 MG CAPSULASClobazam
go.drugbank.com/drugs/DB00349ApprovedIllicitInvestigational[A256963,A256868] This is likely because of clobazam's higher affinity to the α<sub>2</sub> subunit of the GABA<sub>A</sub> receptor, which mediates anxiolytic effects, than the α<sub>1</sub> subunit, … Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.[A256868].
Products: URBADAN® 20 MG, Frisium 10 mg TablettenDordaviprone
go.drugbank.com/drugs/DB14844ApprovedInvestigational[A274391] Dordaviprone has several modes of action, including the activation of mitochondrial caseinolytic protease P (ClpP), antagonism of the dopamine D2 receptor,[L53833] activation of Activating Transcription … Factor 4 (ATF4), and induction of endoplasmic reticulum (ER) stress response.
Reslizumab
go.drugbank.com/drugs/DB06602ApprovedInvestigationalElevated levels of eosinophils increase the risk for asthma exacerbations, including both allergic forms and nonallergic forms of asthma where eosinophilia is prominent. … Inflammation-predominant asthma, which is chatacterized by eosinophilic infiltration of airway mucosa and elevated levels of eosinophils in the blood, sputum and BAL fluid, is associated with an increased
Tucatinib
go.drugbank.com/drugs/DB11652ApprovedInvestigationalTucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. … It was developed by Seattle Genetics and approved by the FDA on April 17, 2020.
Products: TUKYSA 50 mg film-coated tablets, TUKYSA 150 mg film-coated tabletsPhentolamine
go.drugbank.com/drugs/DB00692ApprovedInvestigationaldoses of phentolamine. … [A261781, A261786] It has several therapeutic uses, including the treatment of hypertensive episodes, prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue
Propolis wax
go.drugbank.com/drugs/DB11355ApprovedInvestigationalPropolis wax is naturally produced by honeybees by mixing the resin or exudate collected from tree buds, sap flows, or other botanical sources with beeswax that contains fatty acids and bee enzymes.
Mixtures: Dr.bro MAN OF SENSE Mans CleanserLumacaftor
go.drugbank.com/drugs/DB09280ApprovedInvestigationalPrior to the development of lumacaftor and [DB08820] (Kalydeco), management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of … of CFTR protein.
Imdevimab
go.drugbank.com/drugs/DB15940ApprovedInvestigational[A221495] On November 21, 2020, the FDA authorized emergency approval of REGN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. … [L39130,L39135] Full safety and efficacy data on imdevimab are not yet available, and further evaluation of this investigational therapy will continue.[L23529,L23539,L14303]